Recombinant COVID-19 Spike Protein S1
Order now: dominika@ksiazkiwnauce.pl
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
10-207 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
10-209 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
10-300 | ProSci | 0.1 mg | 632.4 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
21-805 | ProSci | 50 ug | 468.6 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein |
|||
21-807 | ProSci | 50 ug | 437.1 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) is used as antigen in the Serological ELISA Kit to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma (see SARS-CoV-2 (Spike RBD) IgG Serological ELISA Kit; AG-45B-0020). |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein (biotin) |
|||
21-806 | ProSci | 50 ug | 437.1 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) is used as antigen in the Serological ELISA Kit to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma (see SARS-CoV-2 (Spike RBD) IgG Serological ELISA Kit; AG-45B-0020).This biotinylated version of SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) forms a tetramer in the presence of streptavidin and this tetramer can be used to activate B cell memory to SARS-CoV-2 Spike protein. |
|||
SARS-CoV-2 (COVID-19) Spike Glycoprotein-S1, Recombinant protein |
|||
39-111 | ProSci | 0.05 mg | 1520.7 EUR |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 (COVID-19) Biotinylated Spike S1 Recombinant Protein |
|||
10-208 | ProSci | 0.1 mg | 752.1 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2(COVID-19) Spike Recombinant Protein |
|||
10-411 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
|||
11-073 | ProSci | 0.1 mg | 695.4 EUR |
Description: May down-regulate host tetherin (BST2) by lysosomal degradation, thereby counteracting its antiviral activity. |
|||
SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
|||
20-233 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag |
|||
ICOV2ST1RCHIS100UG | Innovative research | each | 738 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
10-100 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
10-117 | ProSci | 0.1 mg | 752.1 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
10-204 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
10-206 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
10-303 | ProSci | 0.1 mg | 632.4 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein Fc-Avi Tag Lyophilized |
|||
ICOV2STS1RFCAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein Fc-Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein |
|||
10-008 | ProSci | 0.1 mg | 714.3 EUR |
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus. |
|||
SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein |
|||
10-015 | ProSci | 0.1 mg | 714.3 EUR |
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein His-Avi Tag Lyophilized |
|||
ICOV2STS1RHISAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein His-Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) Spike S1 (N501Y) Recombinant Protein |
|||
11-084 | ProSci | 0.1 mg | 651.3 EUR |
Description: A new variant of SARS-CoV-2 is spreading in the UK and is rapidly becoming a global threat. It ischaracterized by multiple mutations in the spike protein. Among them, N501Y is of major concernbecause it involves one of the six key amino acid residues determining a tight interaction of theSARS-CoV-2 receptor-binding domain (RBD) with its cellular receptor angiotensin-converting enzyme2 (ACE2). |
|||
SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein |
|||
10-115 | ProSci | 0.1 mg | 651.3 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein |
|||
10-304 | ProSci | 0.1 mg | 632.4 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Beta Variant (B.1.351, SA) Spike S1 (RBD) Recombinant Protein |
|||
21-809 | ProSci | 50 ug | 619.8 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a new variant of SARS-CoV-2, called B.1.351, was detected in South Africa. This variant carries three mutations in the RBD at the positions 417, 484 and 501 (K417N, E484K, N501Y) and is associated with a higher viral load, which may suggest potential for increased transmissibility. |
|||
SARS-CoV-2 (COVID-19) Beta Variant (B.1.351, SA) Spike S1 (RBD) Recombinant Protein |
|||
21-812 | ProSci | 50 ug | 537.9 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a new variant of SARS-CoV-2, called B.1.351, was detected in South Africa. This variant carries three mutations in the RBD at the positions 417, 484 and 501 (K417N, E484K, N501Y) and is associated with a higher viral load, which may suggest potential for increased transmissibility.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.351 Variant, SA) can be used as antigen in Serological ELISA Kits to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. |
|||
SARS-CoV-2 (COVID-19) Delta Variant Spike S1 (His-Avi Tag) Recombinant Protein |
|||
95-127 | ProSci | 0.05 mg | 386.7 EUR |
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent. |
|||
SARS-CoV-2 (COVID-19) Spike S Trimer Recombinant Protein |
|||
20-182 | ProSci | 0.1 mg | 651.3 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike E Mosaic Recombinant protein |
|||
39-114 | ProSci | 0.05 mg | 556.8 EUR |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 (COVID-19) Spike Recombinant protein (800-1000 aa) |
|||
39-125 | ProSci | 0.05 mg | 556.8 EUR |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 (COVID-19) Spike Recombinant protein (1000-1200 aa) |
|||
39-126 | ProSci | 0.05 mg | 556.8 EUR |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein |
|||
20-232 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Omicron Variant Spike S1 (His-Avi Tag) Recombinant Protein |
|||
95-129 | ProSci | 0.05 mg | 386.7 EUR |
Description: SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, in which the receptor binding domain (RBD) protein contains 15 mutations. Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent. |
|||
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike S1 (RBD) Recombinant Protein |
|||
21-808 | ProSci | 50 ug | 619.8 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a more transmissible variant of SARS-CoV-2, called B.1.1.7, was detected in the south of England. This variant carries a mutation in the RBD at the position 501 (N501Y). |
|||
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike S1 (RBD) Recombinant Protein |
|||
21-811 | ProSci | 50 ug | 537.9 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a more transmissible variant of SARS-CoV-2, called B.1.1.7, was detected in the south of England. This variant carries a mutation in the RBD at the position 501 (N501Y).The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.1.7 Variant, UK) can be used as antigen in Serological ELISA Kits to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag Lyophilized |
|||
ICOV2ST1RCTHISLY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein |
|||
10-075 | ProSci | 0.1 mg | 991.5 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. The S protein has been the main focus of therapeutic and vaccine design as it is highly immunogenic. Both neutralizing antibodies 10,11 and memory T cells 12,13 targeting the S protein are present in the sera of convalescent COVID-19 patients. |
|||
SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein |
|||
10-305 | ProSci | 0.1 mg | 632.4 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Variant Spike Protein RBD (E484D) Recombinant Protein |
|||
21-829 | ProSci | 0.1 mg | 714.3 EUR |
Description: SARS-CoV-2 (COVID-19) Variant Spike Protein RBD (E484D) Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein His Tag |
|||
ICOV2STRBDRHIS100UG | Innovative research | each | 851 EUR |
Description: SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein His Tag |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal Fc His Tag Lyophilized |
|||
ICOV2ST1RCTFCHISLY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal Fc His Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike Glycoprotein-S2, Recombinant protein |
|||
39-112 | ProSci | 0.05 mg | 1520.7 EUR |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein |
|||
10-205 | ProSci | 0.1 mg | 752.1 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Biotinylated Spike S1 Recombinant Protein His-Avi Tag Lyophilized |
|||
ICOV2BTYLDSTS1RHISAVILY100UG | Innovative research | each | 899 EUR |
Description: SARS-CoV-2 (COVID-19) Biotinylated Spike S1 Recombinant Protein His-Avi Tag Lyophilized |
|||
COVID-19 Spike S1 protein a.a. 1 to 800 |
|||
00226-V-100ugvial | Virogen | 100 ug/vial | 150 EUR |
Description: COVID-19 Spike S1 protein a.a. 1 to 800 |
|||
SARS-CoV-2 (COVID-19) Spike (D614G) (Stable Trimer) Recombinant Protein |
|||
21-814 | ProSci | 50 ug | 752.1 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. It has been demonstrated that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein trimers.The recombinant protein SARS-CoV-2 Spike Protein (D614G) (Stable Trimer) (rec.) (His) could be useful for structural biology research, vaccine development, serological diagnostic kit development or neutralizing antibody screening. |
|||
SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein Liquid |
|||
ICOV2TRISTR100UG | Innovative research | each | 1215 EUR |
Description: SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein Liquid |
|||
SARS-CoV-2 (COVID-19) Gamma Variant (P.1, Brazil) Spike S1 (RBD) Variant Recombinant Protein |
|||
21-810 | ProSci | 50 ug | 619.8 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a new variant of SARS-CoV-2, called P.1 was detected in Brazil. This variant carries three mutations in the RBD at the positions 417, 484 and 501 (K417T, E484K, N501Y). The P.1 or Brazilian variant is a form of the SARS-CoV-2 coronavirus that appears to have evolved in Brazil and might have contributed to a surge in cases in the northern city of Manaus. |
|||
SARS-CoV-2 (COVID-19) Gamma Variant (P.1, Brazil) Spike S1 (RBD) Variant Recombinant Protein |
|||
21-813 | ProSci | 50 ug | 537.9 EUR |
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a new variant of SARS-CoV-2, called P.1 was detected in Brazil. This variant carries three mutations in the RBD at the positions 417, 484 and 501 (K417T, E484K, N501Y). The P.1 or Brazilian variant is a form of the SARS-CoV-2 coronavirus that appears to have evolved in Brazil and might have contributed to a surge in cases in the northern city of Manaus.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (P.1 Variant, BR) can be used as antigen in Serological ELISA Kits to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. |
|||
SARS-CoV-2(COVID-19) Spike Recombinant Protein C-Fc Tag Lyophilized |
|||
ICOV2STRCFCLY100UG | Innovative research | each | 851 EUR |
Description: SARS-CoV-2(COVID-19) Spike Recombinant Protein C-Fc Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike Recombinant Protein C-His Tag Lyophilized |
|||
ICOV2STRCHISLY100UG | Innovative research | each | 819 EUR |
Description: SARS-CoV-2 (COVID-19) Spike Recombinant Protein C-His Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag and Avi Tag Lyophilized |
|||
ICOV2ST1RCTHISAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein C-terminal His Tag and Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike-RBD (Sf21 cell) Recombinant Protein His Tag |
|||
ICOV2STRBDSF21CRHIS100UG | Innovative research | each | 851 EUR |
Description: SARS-CoV-2 (COVID-19) Spike-RBD (Sf21 cell) Recombinant Protein His Tag |
|||
SARS-CoV-2 (COVID-19) South African variant (B.1.351) Spike S1 (K417N, E484K, N501Y) Recombinant Protein |
|||
20-183 | ProSci | 0.1 mg | 651.3 EUR |
Description: SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells. It has been reported that the UK and South African strains may have higher transmission capabilities, eventually in part due to amino acid substitutions on the SARS-CoV-2 Spike protein. The results of a study show the N501Y replacement in this region of the interface (present in both the UK and South African strains) should be favorable for the interaction with ACE2, while the K417N and E484K substitutions (South African strain) would seem neutral or even unfavorable. |
|||
2019 nCoV/COVID19 Spike protein S1 Recombinant-His tag (100 µg) |
|||
BSV-COV-PR-36 | BioServUK | 100 ug | Ask for price |
Description: 2020 nCoV/COVID19 Spike protein S1 Recombinant-His tag (100 µg) |
|||
2019 nCoV/COVID19 Spike protein S1 Recombinant-His tag (500 µg) |
|||
BSV-COV-PR-37 | BioServUK | 500 ug | Ask for price |
Description: 2020 nCoV/COVID19 Spike protein S1 Recombinant-His tag (500 µg) |
|||
2019 nCoV/COVID19 Spike protein S Recombinant (S1+S2), His-tag |
|||
BSV-COV-PR-40 | BioServUK | 100 ug | Ask for price |
Description: 2019 nCoV/COVID19 Spike protein S Recombinant (S1+S2), His-tag |
|||
2019 nCoV/COVID19 Spike protein S Recombinant (S1+S2), His-tag |
|||
BSV-COV-PR-41 | BioServUK | 500 ug | Ask for price |
Description: 2019 nCoV/COVID19 Spike protein S Recombinant (S1+S2), His-tag |
|||
SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) Spike S1 (N501Y) Recombinant Protein His-Avi Lyophilized |
|||
ICOV2UKB117SPIKES1N501YRHISAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) Spike S1 (N501Y) Recombinant Protein His-Avi Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein C-terminal His Tag |
|||
ICOV2STRBDRCHIS100UG | Innovative research | each | 738 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein C-terminal His Tag |
|||
SARS-CoV-2 (COVID-19) Omicron Variant (B.1.1.529) Spike RBD Recombinant Protein |
|||
21-844 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biologicalprocesses that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Knownreceptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein ofcoronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Mostnotable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike(S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogenand a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells throughinteraction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits,S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibodyand T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Beta Variant ( B.1.351, SA) Spike RBD Recombinant Protein |
|||
21-825 | ProSci | 0.1 mg | 1186.8 EUR |
Description: All viruses undergo fast mutations and adept quickly to the countermeasures that the immune systems creates against them. SARS-CoV-2 of the COVID-19 pandemic is no exception here. During the pandemic multiple mutant strains arose. To help the science combat these mutants ProSci offers the RB-Domains of these mutant SPIKE proteins. That is the full Receptor-Binding Domain of the SPIKE surface protein SARS-CoV-2 of the mutant strain B.1.351, also commonly known as the "SA / South Africa mutant". |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein Fc-Avi Tag Lyophilized |
|||
ICOV2STRBDRFCAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein Fc-Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein His-Avi Tag Lyophilized |
|||
ICOV2STRBDRHISAVILY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein His-Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Omicron Variant (B.1.1.529) Spike Trimer Recombinant Protein |
|||
21-845 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biologicalprocesses that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Knownreceptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein ofcoronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Mostnotable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike(S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogenand a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells throughinteraction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits,S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibodyand T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein C-terminal His Tag |
|||
ICOV2STRBDSD1RCHIS100UG | Innovative research | each | 738 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein C-terminal His Tag |
|||
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike RBD Recombinant Protein |
|||
21-824 | ProSci | 0.1 mg | 1186.8 EUR |
Description: All viruses undergo fast mutations and adept quickly to the countermeasures that the immune systems creates against them. SARS-CoV-2 of the COVID-19 pandemic is no exception here. During the pandemic multiple mutant strains arose. To help the science combat these mutants ProSci offers the RB-Domains of these mutant SPIKE proteins. That is the full RBD domain of the SPIKE surface protein SARS-CoV-2 of the mutant strain B.1.1.7, also commonly known as the "UK / Great Britain mutant". |
|||
SARS-CoV-2 (COVID-19) Variant (B.1.160, 20A.EU2) Spike RBD (S477N) Recombinant Protein |
|||
20-181 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
COVID-19 Spike-E-M Immunodominant regions recombinant antigen |
|||
00220-V-100ugvial | Virogen | 100 ug/vial | 150 EUR |
Description: COVID-19 Spike-E-M Immunodominant regions recombinant antigen |
|||
SARS-CoV-2 (COVID-19) Gamma Variant (P.1, Brazil) Spike RBD Recombinant Protein |
|||
21-826 | ProSci | 0.1 mg | 1186.8 EUR |
Description: All viruses undergo fast mutations and adept quickly to the countermeasures that the immune systems creates against them. SARS-CoV-2 of the COVID-19 pandemic is no exception here. During the pandemic multiple mutant strains arose. To help the science combat these mutants ProSci offers the RB-Domains of these mutant SPIKE proteins. That is the full RBD domain of the SPIKE surface protein SARS-CoV-2 of the mutant strain P.1, also commonly known as the "Brazil". |
|||
SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein C-terminal His Tag |
|||
ICOV2STRBDSD1SD2RCHIS100UG | Innovative research | each | 738 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein C-terminal His Tag |
|||
SARS-CoV-2 (COVID-19) Delta Variant Spike RBD (His-Avi Tag) Recombinant Protein |
|||
95-126 | ProSci | 0.05 mg | 386.7 EUR |
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent. |
|||
SARS-CoV-2 (COVID-19) Variant (B.1.429, Ca .20C) Spike RBD (L452R) Recombinant Protein |
|||
20-180 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein C-terminal His Tag Lyophilized |
|||
ICOV2SRBDRCTHISLY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein C-terminal His Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein mFc Tag C-terminal Lyophilized |
|||
ICOV2SRBDRCTMFCLY100UG | Innovative research | each | 899 EUR |
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein mFc Tag C-terminal Lyophilized |
|||
SARS-CoV-2 (COVID-19) Omicron Variant Spike RBD (His-Avi Tag) Recombinant Protein |
|||
95-128 | ProSci | 0.05 mg | 386.7 EUR |
Description: SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, in which the receptor binding domain (RBD) protein contains 15 mutations. Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent. |
|||
2019 nCoV/COVID19 Spike protein S1 Recombinant, His-tag, Biotinylated (100 µg) |
|||
BSV-COV-PR-38 | BioServUK | 100 ug | Ask for price |
Description: 2020 nCoV/COVID19 Spike protein S1 Recombinant, His-tag, Biotinylated (100 µg) |
|||
2019 nCoV/COVID19 Spike protein S1 Recombinant, His-tag, Biotinylated (500 µg) |
|||
BSV-COV-PR-39 | BioServUK | 500 ug | Ask for price |
Description: 2020 nCoV/COVID19 Spike protein S1 Recombinant, His-tag, Biotinylated (500 µg) |
|||
SARS-CoV-2 (COVID-19) Full-Length Beta Variant (B.1.351, SA) Spike Recombinant Protein |
|||
21-819 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent.; This is the spike protein of the mutant strain B.1.351, also commonly known as the "South Africa mutant". |
|||
SARS-CoV-2 (COVID-19) Full-Length Eta Variant (B.1.525, UK) Spike Recombinant Protein |
|||
21-821 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent. This is the SPIKE protein of the mutant strain B.1.525. |
|||
SARS-CoV-2 (COVID-19) Delta Variant (B.1.617.2) Spike RBD (L452R, T478K) Recombinant Protein |
|||
21-831 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein C-terminal His Tag Lyophilized |
|||
ICOV2S2ECDRCTHISLY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein C-terminal His Tag Lyophilized |
|||
COVID-19 Spike Protein a.a. 1000-12000 |
|||
00223-V-100ugvial | Virogen | 100 ug/vial | 150 EUR |
Description: COVID-19 Spike Protein a.a. 1000-12000 |
|||
SARS-CoV-2 (COVID-19) Full-Length Epsilon Variant (B.1.429, Ca) Spike Recombinant Protein |
|||
21-822 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent. This is the spike protein of the mutant strain B.1.429, also known as mutant strain CAL.20C or "California mutant". |
|||
SARS-CoV-2 (COVID-19) Full-Length Alpha Variant (B.1.1.7, UK) Spike Recombinant Protein |
|||
21-818 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent.; This is the spike protein of the mutant strain B.1.1.7, also commonly known as the "UK / Great Britain mutant". |
|||
SARS-CoV-2 (COVID-19) Full-Length Kappa Variant (B.1.617.1, India) Spike Recombinant Protein |
|||
21-823 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent. This is the spike protein of the mutant strain B.1.429, also known as mutant strain CAL.20C or "California mutant". |
|||
SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein His-Avi Tag Lyophilized |
|||
ICOV2BTYLDSTRBDRHISAVILY100UG | Innovative research | each | 899 EUR |
Description: SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein His-Avi Tag Lyophilized |
|||
SARS-CoV-2 (COVID-19) Full-Length Gamma Variant (P.1, Brazil) Spike Recombinant Protein |
|||
21-820 | ProSci | 0.025 mg | 796.2 EUR |
Description: All viruses undergo fast mutations and adapt quickly to the countermeasures that the immune systems creates. SARS-CoV-2 of the COVID-19 pandemic is no exception to this. During the pandemic multiple mutant strains arose. To help the sciencific community to combat these mutants ProSci offers the SPIKE protein of the mutants in full-length and active in their native trimeric form, stabilized with the LMNG detergent.; This is the spike protein of the mutant strain P.1, also commonly known as the "Brazil". |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
10-409 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
10-422 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
10-423 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2(COVID-19) S1 Recombinant Protein |
|||
10-424 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
10-428 | ProSci | 0.1 mg | 651.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
97-086 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
97-087 | ProSci | 0.1 mg | 752.1 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
97-092 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
92-727 | ProSci | 0.05 mg | 468.6 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein |
|||
92-731 | ProSci | 0.05 mg | 556.8 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Kappa Variant (B.1.617, India) Spike RBD (E484Q, L452R) Recombinant Protein |
|||
20-185 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
COVID-19 Spike Protein a.a. 800 to 1000 |
|||
00222-V-100ugvial | Virogen | 100 ug/vial | 150 EUR |
Description: COVID-19 Spike Protein a.a. 800 to 1000 |
|||
SARS-CoV-2 (COVID-19) Lambda Variant (B.1.1.1/C.37) Spike RBD (L452Q, F490S) Recombinant Protein |
|||
21-828 | ProSci | 0.1 mg | 714.3 EUR |
Description: SARS-CoV-2 (COVID-19) Lambda Variant (B.1.1.1/C.37) Spike RBD (L452Q, F490S) Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Delta plus Variant (B.1.617.2.1) Spike RBD (K417N, T478K, L452R) Recombinant Protein |
|||
21-827 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Antibody |
|||
9083-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike S1 Antibody |
|||
9083-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Mu Variant (B.1.621) Spike RBD (R346K, E484K, N501Y, D614G, P681H) Recombinant Protein |
|||
21-830 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biologicalprocesses that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Knownreceptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein ofcoronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Mostnotable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike(S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogenand a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells throughinteraction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits,S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibodyand T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein NTD |
|||
11-198 | ProSci | 0.1 mg | 714.3 EUR |
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 (D614G) Recombinant Protein |
|||
92-746 | ProSci | 0.05 mg | 500.1 EUR |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein Liquid |
|||
ICOV2S1R100UG | Innovative research | each | 923 EUR |
Description: SARS-CoV-2 (COVID-19) S1 Recombinant Protein Liquid |
|||
SARS-CoV-2 (COVID-19) S1 Protein CTD Recombinant Protein |
|||
92-739 | ProSci | 0.05 mg | 468.6 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin) |
|||
9083-biotin-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin) |
|||
9083-biotin-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
COVID-19 Spike Protein Receptor Binding Domain a.a. 300-600 |
|||
00224-V-100ugvial | Virogen | 100 ug/vial | 150 EUR |
Description: COVID-19 Spike Protein Receptor Binding Domain a.a. 300-600 |
|||
MERS Spike S1 Recombinant protein |
|||
39-102 | ProSci | 0.1 mg | 556.8 EUR |
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis. |
|||
SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein |
|||
10-108 | ProSci | 0.1 mg | 1186.8 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein |
|||
10-121 | ProSci | 0.1 mg | 1186.8 EUR |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
|||
2019 nCoV/COVID19 RBD domain of spike recombinant protein (S)- Fc tag |
|||
BSV-COV-PR-44 | BioServUK | 100 ug | Ask for price |
Description: 2019 nCoV/COVID19 RBD domain of spike recombinant protein (S)- Fc tag (100 ug) |
|||
2019 nCoV/COVID19 RBD domain of spike recombinant protein (S)- Fc tag |
|||
BSV-COV-PR-45 | BioServUK | 500 ug | Ask for price |
Description: 2019 nCoV/COVID19 RBD domain of spike recombinant protein (S)- Fc tag (500 ug) |
|||
SARS-CoV-2 (COVID-19) Omicron Variant (B.1.1.529) S1 Recombinant Protein |
|||
21-846 | ProSci | 0.1 mg | 714.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biologicalprocesses that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Knownreceptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein ofcoronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Mostnotable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike(S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogenand a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells throughinteraction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits,S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibodyand T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) S1 Recombinant Protein N-His Tag Lyophilized |
|||
ICOV2S1RNHISLY100UG | Innovative research | each | 762 EUR |
Description: SARS-CoV-2 (COVID-19) S1 Recombinant Protein N-His Tag Lyophilized |
|||
Human SARS-CoV-2 (COVID-19) S1 Recombinant Protein Fc Tag Lyophilized |
|||
IHUCOV2S1RFCLY100UG | Innovative research | each | 851 EUR |
Description: Human SARS-CoV-2 (COVID-19) S1 Recombinant Protein Fc Tag Lyophilized |
|||
2019 nCoV/COVID19 RBD domain of spike recombinant protein (S), Biotinylated |
|||
BSV-COV-PR-46 | BioServUK | 100 ug | Ask for price |
Description: 2019 nCoV/COVID19 RBD domain of spike recombinant protein (S), Biotinylated (100 ug) |
|||
2019 nCoV/COVID19 RBD domain of spike recombinant protein (S), Biotinylated |
|||
BSV-COV-PR-47 | BioServUK | 500 ug | Ask for price |
Description: 2019 nCoV/COVID19 RBD domain of spike recombinant protein (S), Biotinylated (500 ug) |
|||
MERS Spike S1 Recombinant protein His Tag |
|||
IMERSSPIKES1RHIS100UG | Innovative research | each | 648 EUR |
Description: MERS Spike S1 Recombinant protein His Tag |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) spike antibody |
|||
BSV-COV-AB-05 | BioServUK | 25 ul | Ask for price |
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal) |
|||
SARS-CoV-2 (COVID-19) spike antibody |
|||
BSV-COV-AB-06 | BioServUK | 100 ul | Ask for price |
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal) |
|||
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
10-426 | ProSci | 0.1 mg | 651.3 EUR |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) M Recombinant Protein |
|||
10-429 | ProSci | 0.1 mg | 651.3 EUR |
Description: Membrane glycoprotein is involved in the formation and budding of the viral envelope, that is, in the assembly and release of the virus, inhibiting IFN attack. |
|||
SARS-CoV-2 (COVID-19) E Recombinant Protein |
|||
11-072 | ProSci | 0.1 mg | 695.4 EUR |
Description: Coronavirus envelope (E) proteins are short (100 residues) polypeptides that contain at least one transmembrane (TM) domain and a cluster of 2-3 juxtamembrane cysteines. These proteins are involved in viral morphogenesis and tropism, and their absence leads in some cases to aberrant virions, or to viral attenuation. In common to other viroporins, coronavirus envelope proteins increase membrane permeability to ions, plays a central role in virus morphogenesis and assembly. Acts as a viroporin and self-assembles in host membranes forming pentameric protein-lipid pores that allow ion transport. Also plays a role in the induction of apoptosis. Activates the host NLRP3 inflammasome, leading to IL-1beta overproduction. |
|||
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
11-184 | ProSci | 0.2 mg | 1212 EUR |
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
|||
9091-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
|||
9091-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) RBD Recombinant Protein |
|||
10-078 | ProSci | 0.1 mg | 619.8 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. _x000D__x000D__x000D_Polyclonal RBD-specific antibodies can block ACE2 binding 10, 11, and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients 12, identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition, the RBD is poorly conserved, making it a promising antigen for diagnostic tests 13 14. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients 13 15. Furthermore, the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies, suggesting the RBD could be used to predict an individual's risk of disease 13._x000D_ |
|||
SARS-CoV-2 (COVID-19) NTD Recombinant Protein |
|||
10-079 | ProSci | 0.1 mg | 821.4 EUR |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells3-5. The NTD of SARS-CoV-2 does not bind to ACE26, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties7 and might play a role in the conformational change of S2 required for membrane fusion8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV10. |
|||
SARS-CoV-2 (COVID-19) NSP3 Recombinant Protein |
|||
10-406 | ProSci | 0.1 mg | 651.3 EUR |
Description: The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. |
|||
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
10-415 | ProSci | 0.1 mg | 651.3 EUR |
Description: Cleavage by the viral main protease, 3CLpro results in generating the nsp8 protein, The nsp8 protein has been shown to associate with several other nsps and to colocalize with these nsps in cytoplasmic complexes that are important for viral RNA synthesis. It forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. Nsp8 was shown to have RNA-dependent RNA polymerase (RdRp) activity that could be involved in producing primers utilized by nsp12 which is normally accepted to be the RdRp for SARS-CoV. |
|||
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
10-416 | ProSci | 0.1 mg | 651.3 EUR |
Description: The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ∼30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses. |
|||
SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
10-417 | ProSci | 0.1 mg | 651.3 EUR |
Description: May participate in viral replication by acting as a ssRNA-binding protein. |
|||
SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
10-425 | ProSci | 0.1 mg | 651.3 EUR |
Description: The positive-stranded RNA genome of the coronaviruses is translated from ORF1 to yield polyproteins that are proteolytically processed into intermediate and mature nonstructural proteins (nsps). SARS-CoV 2 polyproteins incorporate 16 protein domains (nsps). The putative non-structural protein 2 (nsp2) of SARS-CoV plays an important role in viral transcription and replication, and is an attractive target for anti-SARS drug development. |
|||
SARS-CoV-2 (COVID-19) ORF8 Recombinant protein |
|||
10-436 | ProSci | 0.1 mg | 695.4 EUR |
Description: May play a role in host-virus interaction. |
|||
SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
10-002 | ProSci | 0.1 mg | 714.3 EUR |
Description: LOCUS: QHD43422 121aa linear VRL 18-MAR-2020 |
|||
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-187 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-188 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
20-192 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
20-212 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
20-213 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
20-214 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-215 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
20-217 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
20-218 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
20-237 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
20-249 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
20-250 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
20-251 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-252 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
20-254 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
20-255 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
97-095 | ProSci | 0.1 mg | 821.4 EUR |
Description: The viral nonstructural protein 1 (nsP1) is the only membrane-associated protein that anchors the replication complex to the cellular membranes. NSP1 inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response. |
|||
SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
97-096 | ProSci | 0.1 mg | 821.4 EUR |
Description: During the formation of the coronaviral replication/transcription complex, essential steps include processing of the conserved polyprotein nsp7-10 region by the main protease Mpro and subsequent complex formation of the released nsp's. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. non-structural proteins 7 (NSP7) forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. |
|||
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
97-097 | ProSci | 0.1 mg | 821.4 EUR |
Description: NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity. |
|||
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
92-764 | ProSci | 0.05 mg | 651.3 EUR |
Description: The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ∼30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses. |
|||
Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
Spike-191V | Creative BioMart | 100ug | 950.4 EUR |
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to His tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
Spike-192V | Creative BioMart | 100ug | 950.4 EUR |
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Human IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
Recombinant 2019-nCoV coronavirus Spike protein S1 subunit |
|||
Spike-193V | Creative BioMart | 100ug | 1932 EUR |
Description: Recombinant COVID-19 (2019 novel coronavirus) Spike protein S1 subunit was fused to to Mouse IgG1 Fc tag at C-terminus and expressed in human cells. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. |
|||
SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein |
|||
10-408 | ProSci | 0.1 mg | 651.3 EUR |
Description: Nsp10 have shown that it is a 15-kDa protein of unknown function that has been shown to interact with itself, nsp1, and nsp7. It colocalizes with N to sites of viral replication and is essential for replication. It plays a pivotal role in viral transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16 2'-O-methyltransferase activities. Therefore plays an essential role in viral mRNAs cap methylation. Nsp10 is a critical regulator of coronavirus RNA synthesis and may play an important role in polyprotein processing. |
|||
SARS-CoV-2 (COVID-19) NSP16 Recombinant Protein |
|||
10-418 | ProSci | 0.1 mg | 651.3 EUR |
Description: Nsp14 and nsp16, are involved in viral mRNA cap formation. The crystalstructure of nsp16 is unknown. Nsp16 is an RNA-cap Adomet-dependent(nucleoside-2 -o-)methyltransferase that is only active in the presence of nsp10. |
|||
SARS-CoV-2 (COVID-19) NSP12 Recombinant Protein |
|||
10-419 | ProSci | 0.1 mg | 651.3 EUR |
Description: SARS-CoV-2 (COVID-19) NSP12 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
10-420 | ProSci | 0.1 mg | 651.3 EUR |
Description: SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP13 Recombinant Protein |
|||
10-427 | ProSci | 0.1 mg | 651.3 EUR |
Description: SARS-CoV-2 (COVID-19) NSP13 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF7a Recombinant protein |
|||
10-435 | ProSci | 0.1 mg | 695.4 EUR |
Description: Plays a role as antagonist of host tetherin (BST2), disrupting its antiviral effect. Acts by binding to BST2 thereby interfering with its glycosylation. May suppress small interfering RNA (siRNA). May bind to host ITGAL, thereby playing a role in attachment or modulation of leukocytes. |
|||
SARS-CoV-2 (COVID-19) ORF3a Recombinant Protein |
|||
10-005 | ProSci | 0.1 mg | 714.3 EUR |
Description: LOCUS: QHD43417 275aa linear VRL 18-MAR-2020 |
|||
SARS-CoV-2 (COVID-19) ORF10 Recombinant Protein |
|||
20-189 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF10 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF9B Recombinant Protein |
|||
20-190 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF9B Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF9A Recombinant Protein |
|||
20-191 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF9A Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP16 Recombinant Protein |
|||
20-206 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP16 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
20-207 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP14 Recombinant Protein |
|||
20-208 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP14 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP13 Recombinant Protein |
|||
20-209 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP13 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein |
|||
20-211 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF10 Recombinant Protein |
|||
20-234 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF10 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF9B Recombinant Protein |
|||
20-235 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF9B Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF9A Recombinant Protein |
|||
20-236 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF9A Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF7B Recombinant Protein |
|||
20-238 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF7B Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) ORF3A Recombinant Protein |
|||
20-242 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) ORF3A Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP16 Recombinant Protein |
|||
20-243 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP16 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
20-244 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP15 Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein |
|||
20-248 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) NSP10 Recombinant Protein |
|||
Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag) |
|||
P1541-10 | Biovision | 10 µg | 211.2 EUR |
Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag) |
|||
P1541-50 | Biovision | 50 µg | 818.4 EUR |
SARS-CoV-2 (COVID-19) Envelope Recombinant Protein |
|||
10-112 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Envelope Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Membrane Recombinant Protein |
|||
20-203 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Membrane Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Membrane Recombinant Protein |
|||
20-230 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Membrane Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Envelope Recombinant Protein |
|||
20-231 | ProSci | 0.1 mg | 726.9 EUR |
Description: SARS-CoV-2 (COVID-19) Envelope Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Envelope Recombinant Protein |
|||
97-082 | ProSci | 0.1 mg | 714.3 EUR |
Description: The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein. |